<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33020464</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>19</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The ALS-related &#x3c3;1R E102Q Mutant Eludes Ligand Control and Exhibits Anomalous Response to Calcium.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7339</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21197339</ELocationID><Abstract><AbstractText>Sigma receptor type 1 (&#x3c3;1R) is a transmembrane protein expressed throughout the central nervous system and in certain peripheral tissues. The human &#x3c3;1R E102Q mutation causes juvenile amyotrophic lateral sclerosis (ALS), likely by inducing a series of alterations in calcium efflux from the endoplasmic reticulum (ER) to mitochondria that affects calcium homeostasis and cellular survival. Here, we report the influence of calcium on &#x3c3;1R E102Q associations with glutamate N-methyl-D-aspartate receptors (NMDARs), binding immunoglobulin protein (BiP), and transient receptor potential calcium channels A1, V1, and M8. The mutant protein inhibited the binding of calmodulin to these calcium channels and interacted less with BiP than wild-type &#x3c3;1R, thereby contributing to calcium homeostasis dysfunction. Mutant &#x3c3;1R, but not wild-type &#x3c3;1R, strongly bound to histidine triad nucleotide binding protein 1, which regulates neuromuscular synaptic organization and target selection through teneurin 1. While ligands regulated the association of &#x3c3;1R wild-type with NMDARs and BiP, they failed to modulate the interaction between these proteins and the &#x3c3;1R E102Q mutant. Thus, the &#x3c3;1R E102Q mutant exhibited an anomalous response to cytosolic calcium levels, altered affinity for target proteins, and a loss of response to regulatory ligands. We believe that these modifications may contribute to the onset of juvenile ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Mu&#xf1;oz</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropharmacology, Cajal Institute, CSIC, Avenida Doctor Arce, 37. 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cort&#xe9;s-Montero</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuropharmacology, Cajal Institute, CSIC, Avenida Doctor Arce, 37. 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garz&#xf3;n-Ni&#xf1;o</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuropharmacology, Cajal Institute, CSIC, Avenida Doctor Arce, 37. 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Bl&#xe1;zquez</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuropharmacology, Cajal Institute, CSIC, Avenida Doctor Arce, 37. 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RT 2018-093677-B-100</GrantID><Agency>Ministerio Cienciia e Innovacion, Spain</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002136">Calcium, Dietary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106106">sigma-1 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002136" MajorTopicYN="N">Calcium, Dietary</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="N">Receptors, sigma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">E102Q mutation</Keyword><Keyword MajorTopicYN="N">N-methyl-D-aspartate receptor</Keyword><Keyword MajorTopicYN="N">binding immunoglobulin protein</Keyword><Keyword MajorTopicYN="N">juvenile amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">sigma type receptor 1</Keyword><Keyword MajorTopicYN="N">transient receptor potential calcium channels</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The authors declare that all the research presented here was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33020464</ArticleId><ArticleId IdType="pmc">PMC7582951</ArticleId><ArticleId IdType="doi">10.3390/ijms21197339</ArticleId><ArticleId IdType="pii">ijms21197339</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gundlach A.L., Largent B.L., Snyder S.H. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 1986;6:1757&#x2013;1770. doi: 10.1523/JNEUROSCI.06-06-01757.1986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.06-06-01757.1986</ArticleId><ArticleId IdType="pmc">PMC6568729</ArticleId><ArticleId IdType="pubmed">3012017</ArticleId></ArticleIdList></Reference><Reference><Citation>Largent B.L., Gundlach A.L., Snyder S.H. Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharm. Exp. 1986;238:739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">3016248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zukin S.R., Tempel A., Gardner E.L., Zukin R.S. Interaction of [3H](-)-SKF-10,047 with brain sigma receptors: Characterization and autoradiographic visualization. J. Neurochem. 1986;46:1032&#x2013;1041. doi: 10.1111/j.1471-4159.1986.tb00614.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1986.tb00614.x</ArticleId><ArticleId IdType="pubmed">3005501</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker J.M., Bowen W.D., Goldstein S.R., Roberts A.H., Patrick S.L., Hohmann A.G., DeCosta B. Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: A comparative study. Brain Res. 1992;581:33&#x2013;38. doi: 10.1016/0006-8993(92)90340-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(92)90340-F</ArticleId><ArticleId IdType="pubmed">1323368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim F.J., Kovalyshyn I., Burgman M., Neilan C., Chien C.C., Pasternak G.W. Sigma 1 receptor modulation of G-protein-coupled receptor signaling: Potentiation of opioid transduction independent from receptor binding. Mol. Pharm. 2010;77:695&#x2013;703. doi: 10.1124/mol.109.057083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.109.057083</ArticleId><ArticleId IdType="pmc">PMC2845939</ArticleId><ArticleId IdType="pubmed">20089882</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro G., Moreno E., Aymerich M., Marcellino D., McCormick P.J., Mallol J., Cortes A., Casado V., Canela E.I., Ortiz J., et al. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc. Natl Acad Sci USA. 2010;107:18676&#x2013;18681. doi: 10.1073/pnas.1008911107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008911107</ArticleId><ArticleId IdType="pmc">PMC2972946</ArticleId><ArticleId IdType="pubmed">20956312</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Bl&#xe1;zquez P., Rodr&#xed;guez-Mu&#xf1;oz M., Herrero-Labrador R., Burgue&#xf1;o J., Zamanillo D., Garz&#xf3;n J. The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: Implications in antinociception and psychotic diseases. Int J. Neuropsychopharmacol. 2014;17:1943&#x2013;1955. doi: 10.1017/S1461145714000029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145714000029</ArticleId><ArticleId IdType="pubmed">24485144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.P. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export. J. Pharm. Exp. 2003;306:718&#x2013;725. doi: 10.1124/jpet.103.051284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.051284</ArticleId><ArticleId IdType="pubmed">12730355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A., Fontanilla D., Gopalakrishnan A., Chae Y.K., Markley J.L., Ruoho A.E. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur. J. Pharm. 2012;682:12&#x2013;20. doi: 10.1016/j.ejphar.2012.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2012.01.030</ArticleId><ArticleId IdType="pmc">PMC3314091</ArticleId><ArticleId IdType="pubmed">22381068</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai S.Y., Chuang J.Y., Tsai M.S., Wang X.F., Xi Z.X., Hung J.J., Chang W.C., Bonci A., Su T.P. Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proc Natl Acad Sci USA. 2015;112:E6562&#x2013;E6570. doi: 10.1073/pnas.1518894112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1518894112</ArticleId><ArticleId IdType="pmc">PMC4664336</ArticleId><ArticleId IdType="pubmed">26554014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596&#x2013;610. doi: 10.1016/j.cell.2007.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.P. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse. Life Sci. 2005;77:1612&#x2013;1624. doi: 10.1016/j.lfs.2005.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2005.05.009</ArticleId><ArticleId IdType="pubmed">16002098</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T., Su T.P. The pharmacology of sigma-1 receptors. Pharmacology. 2009;124:195&#x2013;206. doi: 10.1016/j.pharmthera.2009.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2009.07.001</ArticleId><ArticleId IdType="pmc">PMC2785038</ArticleId><ArticleId IdType="pubmed">19619582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei J., Pasternak G.W. Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem. Pharm. 2001;62:349&#x2013;355. doi: 10.1016/S0006-2952(01)00666-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-2952(01)00666-9</ArticleId><ArticleId IdType="pubmed">11434908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabino V., Cottone P., Parylak S.L., Steardo L., Zorrilla E.P. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198:472&#x2013;476. doi: 10.1016/j.bbr.2008.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2008.11.036</ArticleId><ArticleId IdType="pmc">PMC2667953</ArticleId><ArticleId IdType="pubmed">19100292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro H., Ohtsuki T., Toru M., Itokawa M., Aoki J., Shibuya H., Kurumaji A., Okubo Y., Iwawaki A., Ota K., et al. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett. 1998;257:45&#x2013;48. doi: 10.1016/S0304-3940(98)00797-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00797-6</ArticleId><ArticleId IdType="pubmed">9857962</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Bl&#xe1;zquez P., Pozo-Rodrig&#xe1;lvarez A., Merlos M., Garz&#xf3;n J. The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. Mol. Neurobiol. 2018;55:4940&#x2013;4951. doi: 10.1007/s12035-017-0697-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0697-x</ArticleId><ArticleId IdType="pmc">PMC5948242</ArticleId><ArticleId IdType="pubmed">28779350</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Cui X., Roon P., Saul A., Smith S.B. The Role of Sigma1R in Mammalian Retina. Adv. Exp. Med. Biol. 2017;964:267&#x2013;284. doi: 10.1007/978-3-319-50174-1_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-50174-1_18</ArticleId><ArticleId IdType="pubmed">28315277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov T.A., Nickells R.W., Guo L.W. Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor. Mol. Vis. 2011;17:1034&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084245</ArticleId><ArticleId IdType="pubmed">21541278</ArticleId></ArticleIdList></Reference><Reference><Citation>Villard V., Espallergues J., Keller E., Vamvakides A., Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J. Psychopharmacol. 2011;25:1101&#x2013;1117. doi: 10.1177/0269881110379286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881110379286</ArticleId><ArticleId IdType="pubmed">20829307</ArticleId></ArticleIdList></Reference><Reference><Citation>Francardo V., Bez F., Wieloch T., Nissbrandt H., Ruscher K., Cenci M.A. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137:1998&#x2013;2014. doi: 10.1093/brain/awu107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu107</ArticleId><ArticleId IdType="pubmed">24755275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyrskyluoto A., Pulli I., Tornqvist K., Ho T.H., Korhonen L., Lindholm D. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: Involvement of calpastatin and the NF-kappaB pathway. Cell. Death Dis. 2013;4:e646. doi: 10.1038/cddis.2013.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.170</ArticleId><ArticleId IdType="pmc">PMC3674377</ArticleId><ArticleId IdType="pubmed">23703391</ArticleId></ArticleIdList></Reference><Reference><Citation>Luty A.A., Kwok J.B., Dobson-Stone C., Loy C.T., Coupland K.G., Karlstrom H., Sobow T., Tchorzewska J., Maruszak A., Barcikowska M., et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann. Neurol. 2010;68:639&#x2013;649. doi: 10.1002/ana.22274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22274</ArticleId><ArticleId IdType="pubmed">21031579</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Hu Z., Liu L., Xie Y., Zhan Y., Zi X., Wang J., Wu L., Xia K., Tang B., et al. A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy. Neurology. 2015;84:2430&#x2013;2437. doi: 10.1212/WNL.0000000000001680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001680</ArticleId><ArticleId IdType="pubmed">26078401</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A., Al-Mohanna F., Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2011;70:913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Ilieva H., Tamada H., Nomura H., Komine O., Endo F., Jin S., Mancias P., Kiyama H., Yamanaka K. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. Embo Mol. Med. 2016;8:1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov T.A., Epstein M.L., Andersen K.A., Ziskind-Conhaim L., Ruoho A.E. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167:247&#x2013;255. doi: 10.1016/j.neuroscience.2010.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.02.022</ArticleId><ArticleId IdType="pmc">PMC2862368</ArticleId><ArticleId IdType="pubmed">20167253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N., Medard J.J., Azzedine H., Chrast R. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain. 2015;138:875&#x2013;890. doi: 10.1093/brain/awv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv008</ArticleId><ArticleId IdType="pubmed">25678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H.R., Zheng S., Gurpinar E., Koehl A., Manglik A., Kruse A.C. Crystal structure of the human sigma1 receptor. Nature. 2016;532:527&#x2013;530. doi: 10.1038/nature17391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17391</ArticleId><ArticleId IdType="pmc">PMC5550834</ArticleId><ArticleId IdType="pubmed">27042935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreser A., Vollrath J.T., Sechi A., Johann S., Roos A., Yamoah A., Katona I., Bohlega S., Wiemuth D., Tian Y., et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24:1655&#x2013;1671. doi: 10.1038/cdd.2017.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.88</ArticleId><ArticleId IdType="pmc">PMC5596426</ArticleId><ArticleId IdType="pubmed">28622300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mu&#xf1;oz M., S&#xe1;nchez-Bl&#xe1;zquez P., Herrero-Labrador R., Mart&#xed;nez-Murillo R., Merlos M., Vela J.M., Garz&#xf3;n J. The sigma1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control. Antioxid. Redox Signal. 2015;22:799&#x2013;818. doi: 10.1089/ars.2014.5993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2014.5993</ArticleId><ArticleId IdType="pmc">PMC4367239</ArticleId><ArticleId IdType="pubmed">25557043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mu&#xf1;oz M., Cort&#xe9;s-Montero E., Pozo-Rodrig&#xe1;lvarez A., S&#xe1;nchez-Bl&#xe1;zquez P., Garz&#xf3;n-Ni&#xf1;o J. The ON:OFF switch, sigma1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: Implications in neurological disorders. Oncotarget. 2015;6:35458&#x2013;35477. doi: 10.18632/oncotarget.6064.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6064</ArticleId><ArticleId IdType="pmc">PMC4742118</ArticleId><ArticleId IdType="pubmed">26461475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Montero E., S&#xe1;nchez-Bl&#xe1;zquez P., Onetti Y., Merlos M., Garz&#xf3;n J. Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels. Front. Pharm. 2019;10:634. doi: 10.3389/fphar.2019.00634.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00634</ArticleId><ArticleId IdType="pmc">PMC6582314</ArticleId><ArticleId IdType="pubmed">31249525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Le W.D., Xie Y.Y., Wang X.P. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis. Curr. Neuropharmacol. 2016;14:314&#x2013;321. doi: 10.2174/1570159X14666160120152423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mu&#xf1;oz M., S&#xe1;nchez-Bl&#xe1;zquez P., Garz&#xf3;n J. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget. 2018;9:23373&#x2013;23389. doi: 10.18632/oncotarget.25169.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25169</ArticleId><ArticleId IdType="pmc">PMC5955088</ArticleId><ArticleId IdType="pubmed">29805740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.P. Regulating ankyrin dynamics: Roles of sigma-1 receptors. Proc. Natl. Acad. Sci. USA. 2001;98:491&#x2013;496. doi: 10.1073/pnas.98.2.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.491</ArticleId><ArticleId IdType="pmc">PMC14614</ArticleId><ArticleId IdType="pubmed">11149946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers M.D., Zhang S., Bernhadt J.P., Huganir R.L. Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell. 1996;84:745&#x2013;755. doi: 10.1016/S0092-8674(00)81052-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81052-1</ArticleId><ArticleId IdType="pubmed">8625412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.Y., Hristova E., Ahlskog N., Tasse L.A., Ngsee J.K., Chudalayandi P., Bergeron R. Aberrant Subcellular Dynamics of Sigma-1 Receptor Mutants Underlying Neuromuscular Diseases. Mol. Pharm. 2016;90:238&#x2013;253. doi: 10.1124/mol.116.104018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.116.104018</ArticleId><ArticleId IdType="pubmed">27418673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov. 2006;5:160&#x2013;170. doi: 10.1038/nrd1958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1958</ArticleId><ArticleId IdType="pubmed">16424917</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Montero E., Rodr&#xed;guez-Mu&#xf1;oz M., S&#xe1;nchez-Bl&#xe1;zquez P., Garz&#xf3;n J. The Axonal Motor Neuropathy-Related HINT1 Protein Is a Zinc- and Calmodulin-Regulated Cysteine SUMO Protease. Antioxid. Redox Signal. 2019;31:503&#x2013;520. doi: 10.1089/ars.2019.7724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2019.7724</ArticleId><ArticleId IdType="pmc">PMC6648240</ArticleId><ArticleId IdType="pubmed">31088288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimon M., Baets J., Almeida-Souza L., De V.E., Nikodinovic J., Parman Y., Battaloglu E., Matur Z., Guergueltcheva V., Tournev I., et al. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat. Genet. 2012;44:1080&#x2013;1083. doi: 10.1038/ng.2406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2406</ArticleId><ArticleId IdType="pubmed">22961002</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiske J., Huber O. The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-beta-catenin-mediated transcription. J. Cell Sci. 2005;118:3117&#x2013;3129. doi: 10.1242/jcs.02437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.02437</ArticleId><ArticleId IdType="pubmed">16014379</ArticleId></ArticleIdList></Reference><Reference><Citation>Leamey C.A., Sawatari A. Teneurins: Mediators of Complex Neural Circuit Assembly in Mammals. Front. Neurosci. 2019;13:580. doi: 10.3389/fnins.2019.00580.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00580</ArticleId><ArticleId IdType="pmc">PMC6560073</ArticleId><ArticleId IdType="pubmed">31231187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca T.J., Hong W., Dani V.S., Favaloro V., Luo L. Trans-synaptic Teneurin signalling in neuromuscular synapse organization and target choice. Nature. 2012;484:237&#x2013;241. doi: 10.1038/nature10923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10923</ArticleId><ArticleId IdType="pmc">PMC3326183</ArticleId><ArticleId IdType="pubmed">22426000</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Fukushi M., Kosaki K., Doyle A.D., de Vega S., Yoshizaki K., Akazawa C., Arikawa-Hirasawa E., Yamada Y. Teneurin-4 is a novel regulator of oligodendrocyte differentiation and myelination of small-diameter axons in the CNS. J. Neurosci. 2012;32:11586&#x2013;11599. doi: 10.1523/JNEUROSCI.2045-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2045-11.2012</ArticleId><ArticleId IdType="pmc">PMC3442259</ArticleId><ArticleId IdType="pubmed">22915103</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendra L., Laranjeira F., Fernandez-Marmiesse A., Negrao L. SIGMAR1 gene mutation causing Distal Hereditary Motor Neuropathy in a Portuguese family. Acta Myol. 2018;37:2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060428</ArticleId><ArticleId IdType="pubmed">30079398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregianin E., Pallafacchina G., Zanin S., Crippa V., Rusmini P., Poletti A., Fang M., Li Z., Diano L., Petrucci A., et al. Loss-of-function mutations in the SIGMAR1 gene cause distal hereditary motor neuropathy by impairing ER-mitochondria tethering and Ca2+ signalling. Hum. Mol. Genet. 2016;25:3741&#x2013;3753. doi: 10.1093/hmg/ddw220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw220</ArticleId><ArticleId IdType="pubmed">27402882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah M.I., Ahmad A., Raza S.I., Amar A., Ali A., Bhatti A., John P., Mohyuddin A., Ahmad W., Hassan M.J. In silico analysis of SIGMAR1 variant (rs4879809) segregating in a consanguineous Pakistani family showing amyotrophic lateral sclerosis without frontotemporal lobar dementia. Neurogenetics. 2015;16:299&#x2013;306. doi: 10.1007/s10048-015-0453-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0453-1</ArticleId><ArticleId IdType="pubmed">26205306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga K., Shinoda Y., Tagashira H. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J. Pharm. Sci. 2015;127:36&#x2013;41. doi: 10.1016/j.jphs.2014.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.12.012</ArticleId><ArticleId IdType="pubmed">25704016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp D.A., Zhemkov V., Bezprozvanny I. Mutational Analysis of Sigma-1 Receptor&#x2019;s Role in Synaptic Stability. Front. Neurosci. 2019;13:1012. doi: 10.3389/fnins.2019.01012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01012</ArticleId><ArticleId IdType="pmc">PMC6761230</ArticleId><ArticleId IdType="pubmed">31607852</ArticleId></ArticleIdList></Reference><Reference><Citation>Su T.P., Hayashi T., Maurice T., Buch S., Ruoho A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharm. Sci. 2010;31:557&#x2013;566. doi: 10.1016/j.tips.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC2993063</ArticleId><ArticleId IdType="pubmed">20869780</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramyan A.M., Yano H., Xu M., Liu L., Naing S., Fant A.D., Shi L. The Glu102 mutation disrupts higher-order oligomerization of the sigma 1 receptor. Comput. Struct. Biotechnol. J. 2020;18:199&#x2013;206. doi: 10.1016/j.csbj.2019.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2019.12.012</ArticleId><ArticleId IdType="pmc">PMC7005341</ArticleId><ArticleId IdType="pubmed">32055286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>